GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » ROIC %

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) ROIC % : -172.66% (As of Jan. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Cotinga Pharmaceuticals's annualized return on invested capital (ROIC %) for the quarter that ended in Jan. 2020 was -172.66%.

As of today (2024-06-22), Cotinga Pharmaceuticals's WACC % is 0.00%. Cotinga Pharmaceuticals's ROIC % is 0.00% (calculated using TTM income statement data). Cotinga Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Cotinga Pharmaceuticals ROIC % Historical Data

The historical data trend for Cotinga Pharmaceuticals's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals ROIC % Chart

Cotinga Pharmaceuticals Annual Data
Trend Apr10 Apr11 Apr12 Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -168.55 -126.72 -213.78 -340.99 -267.40

Cotinga Pharmaceuticals Quarterly Data
Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -143.99 -387.71 -221.71 -200.40 -172.66

Competitive Comparison of Cotinga Pharmaceuticals's ROIC %

For the Biotechnology subindustry, Cotinga Pharmaceuticals's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cotinga Pharmaceuticals's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's ROIC % distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's ROIC % falls into.



Cotinga Pharmaceuticals ROIC % Calculation

Cotinga Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Apr. 2019 is calculated as:

ROIC % (A: Apr. 2019 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Apr. 2018 ) + Invested Capital (A: Apr. 2019 ))/ count )
=-2.055 * ( 1 - 0% )/( (0.832 + 0.705)/ 2 )
=-2.055/0.7685
=-267.40 %

where

Cotinga Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jan. 2020 is calculated as:

ROIC % (Q: Jan. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2019 ) + Invested Capital (Q: Jan. 2020 ))/ count )
=-1.44 * ( 1 - 0% )/( (0.79 + 0.878)/ 2 )
=-1.44/0.834
=-172.66 %

where

Note: The Operating Income data used here is four times the quarterly (Jan. 2020) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cotinga Pharmaceuticals  (OTCPK:COTQF) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Cotinga Pharmaceuticals's WACC % is 0.00%. Cotinga Pharmaceuticals's ROIC % is 0.00% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Cotinga Pharmaceuticals ROIC % Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire 05-22-2019